Healthcare Business Recap: Achillion’s Hepatitis Results, Endocyte Drug Gets Orphan Status

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Achillion Pharmaceuticals (NASDAQ:ACHN) announceses positive proof-of-concept results for ACH-3102 for the treatment of chronic hepatitis C viral infections (HCV). The firm has now begun a phase II evaluation for the drug.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Endocyte’s (NASDAQ:ECYT) folic acid solution for helping to treat ovarian cancer has been awarded orphan status by the European Commission. The solution is employed as a pre-injection for the radiodiagnostic imaging agent, etarfolatide, in selecting patients who can be treated with Endocyte’s vintafolide drug. Endocyte and Merck & Co. (NYSE:MRK) are developing the latter med, which is Phase II and III cancer trials.

Shares of StemCells (NASDAQ:STEM) pop on word that its proprietary HuCNS-SC neural stem cells have now been transplanted for the first time into a patient suffering from an incomplete spinal cord injury. Earlier in September, StemCells reported that two out of three patients with complete injuries experienced restored sensation subsequent to receiving the company’s stem cells.

Don’t Miss: Starbucks: Here’s Our New Plan to Take Over Europe.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business